November 18, 2025
RA Jainee
Nippon India Pharma Fund details, NAV, Portfolio, Returns, Peer Comparison, Fund Managers & Guidance by sahifund.com
NAV Growth: Rs 579.9792
NAV IDCW: Rs 171.2582
Bonus NAV: Rs 579.9792
Suitable For Which Investors?
This is a fund that invests mainly in shares of pharmaceutical and healthcare companies.
We believe that investors should avoid funds that have a narrowly defined investment mandate such as this one. Instead, they should invest in flexi-cap funds which provide complete freedom to the fund management team to invest in companies from which it expects maximum gains.
But if you do invest, you must do so only through the SIP route.
Fund’s Investment Strategy:
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
Fund Manager:
1) Sailesh Raj Bhan
Education: Mr. Bhan is an MBA (Finance) and CFA.
Experience: Prior to joining Nippon India Mutual Fund, he has worked with Emkay Share & Stock Broker Pvt. Ltd, Shah & Sequeira Invst. Pvt. Ltd, ICFAI- Securities Research Center Analyst – Equity Research.
Investment Details
| Min. Investment (₹) | 5,000 |
| Min. Addl Investment (₹) | 1,000 |
| Min. SIP Investment (₹) | 100 |
| Min. Withdrawal (₹) | 100 |
| Min. No of Cheques | 60 |
| Min. Balance (₹) | 1 |
| Lock-in Period | NA |
| Exit Load | 1% for redemption within 30 days |
Basic Details of Nippon India Pharma Fund
| Fund House | Nippon India Mutual Fund |
| Launch Date | 01-Jan-13 |
| Return Since Launch | 17.87% |
| Benchmark | BSE Healthcare TRI |
| Riskometer | Very High |
| Type | Open-ended |
| Assets | ₹ 8,346 Cr |
| (As on 31-Oct-2025) | |
| Expense | 0.89% |
| (As on 31-Oct-2025) | |
| Risk Grade | Average |
| Return Grade | Average |
| Turnover | 16.00% |
Trailing Returns (%)
| Fund name | YTD | 1D | 1M | 3M | 6M | 1Y | 3Y | 5Y | 7Y | 10Y |
| Nippon India Pharma Dir | -0.72 | 0.35 | 1.87 | 0.16 | 5.63 | 5.23 | 22.65 | 18.80 | 20.24 | 14.61 |
| BSE Healthcare TRI | -0.84 | 0.22 | 0.61 | 0.50 | 6.05 | 5.63 | 24.09 | 18.22 | 18.50 | 11.25 |
| Equity: Sectoral-Pharma | -0.05 | 0.35 | 1.29 | 0.94 | 7.04 | 5.88 | 23.35 | 18.61 | 21.58 | 13.57 |
| Rank within category | 14 | 11 | 7 | 16 | 18 | 12 | 7 | 6 | 6 | 1 |
| Number of funds in category | 21 | 23 | 23 | 23 | 21 | 18 | 11 | 10 | 6 | 3 |
Peer Comparison of Nippon India Pharma Fund
| Rating | 1 Year Returns | 3 Year Returns | 5 Year Returns | Expense Ratio (%) | Net Assets (Rs Cr) | Return Since Launch (%) | Exit Load (Days) | Fund Age | Turnover (%) | |
| Nippon India Pharma Dir | 3 star | 5.23 | 22.65 | 18.80 | 0.89 | 8,346 | 17.87 | 1.00 (30) | 12Y 10M | 16.00 |
| ICICI Pru Pharma Healthcare and Diagnostics Dir | 5 star | 9.32 | 28.67 | 21.68 | 1.03 | 6,437 | 22.34 | 1.00 (15) | 7Y 4M | 60.00 |
| SBI Healthcare Opportunities Dir | 5 star | 6.10 | 25.89 | 20.61 | 0.91 | 4,082 | 17.85 | 0.50 (15) | 12Y 10M | 14.00 |
| DSP Healthcare Dir | 4 star | 0.09 | 23.00 | 19.18 | 0.56 | 3,144 | 23.79 | 0.50 (30) | 6Y 11M | 13.00 |
| UTI Healthcare Dir | 4 star | 5.01 | 24.88 | 18.62 | 1.31 | 1,125 | 16.15 | 1.00 (30) | 12Y 10M | 32.00 |
Portfolio Analysis of Nippon India Pharma Fund
| No. of Stocks | 36 |
| Top 10 Stocks | 58.54% |
| Top 5 Stocks | 40.26% |
| Top 3 Sectors | 99.67% |
| Portfolio P/B Ratio | 5.49 |
| Portfolio P/E Ratio | 37.13 |
Portfolio Breakup
| Fund | Category | |
| Average Mkt Cap (Rs Cr) | 61,310 | 79,618 |
| Giant (%) | 21.41 | 22.43 |
| Large (%) | 30.85 | 32.83 |
| Mid (%) | 31.99 | 38.41 |
| Small (%) | 15.74 | 12.00 |
| Tiny (%) | — | 0.10 |
Chanakya’s Mutual Fund Guidance For Nippon India Pharma Fund
WILL POST SOON
Disclaimer: Mutual fund investments are subject to market risks. Read all scheme related documents carefully
Apply Online: https://invest.nipponindiaim.com/#/auth/landingPage?redirect=login
>> Post your MF questions @ sahifund.com/ask-me/
>> NFO Guidance:
https://sahifund.com/category/nfos/
Quicklinks
- Chanakyanipothi.com
- Staffavailable.com
- BigGaddi.com
- Latest IPO GMP
- Best Stocks to buy today
- Grey Market Premium
- Upcoming IPOs
- Subscription Status